A
Angelo Paci
Researcher at Institut Gustave Roussy
Publications - 171
Citations - 4276
Angelo Paci is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Busulfan & Population. The author has an hindex of 30, co-authored 164 publications receiving 3382 citations. Previous affiliations of Angelo Paci include Université Paris-Saclay & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine E. Yen,Jeremy Travins,Fang Wang,Muriel D. David,Muriel D. David,Erin Artin,Kimberly Straley,Anil K. Padyana,Stefan Gross,Byron DeLaBarre,Erica Tobin,Yue Chen,Raj Nagaraja,Sung Choe,Lei Jin,Zenon D. Konteatis,Giovanni Cianchetta,Jeffrey O. Saunders,Francesco G. Salituro,Cyril Quivoron,Cyril Quivoron,Paule Opolon,Olivia Bawa,Véronique Saada,Véronique Saada,Angelo Paci,Sophie Broutin,Olivier Bernard,Olivier Bernard,Stéphane de Botton,Stéphane de Botton,Benoit S. Marteyn,Benoit S. Marteyn,Monika Pilichowska,Yingxia Xu,Cheng Fang,Fan Jiang,Wentao Wei,Shengfang Jin,Lee Silverman,Wei Liu,Hua Yang,Lenny Dang,Marion Dorsch,Virginie Penard-Lacronique,Virginie Penard-Lacronique,Scott A. Biller,Shin-San Michael Su +47 more
TL;DR: It is shown that the targeted inhibitor AG-221 suppresses the mutant IDH2 enzyme in multiple preclinical models and induces differentiation of malignant blasts, supporting its clinical development.
Journal ArticleDOI
Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Nicolas Widmer,Christophe Bardin,Etienne Chatelut,Angelo Paci,Jos H. Beijnen,Dominique Levêque,Gareth J. Veal,Alain Astier +7 more
TL;DR: Applications for TDM during oral targeted therapies may best be reserved for particular situations including lack of therapeutic response, severe or unexpected toxicities, anticipated drug-drug interactions and/or concerns over adherence treatment.
Journal ArticleDOI
Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
Angelo Paci,Gareth J. Veal,Christophe Bardin,Dominique Levêque,Nicolas Widmer,Jos H. Beijnen,Alain Astier,Etienne Chatelut +7 more
TL;DR: Considerable effort should be made to better define concentration-effect relationships and to utilise tools such as population PK/PD models and comparative randomised trials of classic dosing versus pharmacokinetically guided adaptive dosing to promote TDM guidelines among the oncological community.
Journal ArticleDOI
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer.
Clélia Coutzac,Jean Mehdi Jouniaux,Jean Mehdi Jouniaux,Angelo Paci,Angelo Paci,Julien Schmidt,Julien Schmidt,Domenico Mallardo,Atmane Seck,V. Asvatourian,V. Asvatourian,Lydie Cassard,Patrick Saulnier,Ludovic Lacroix,Paul Louis Woerther,Aurore Vozy,M. Naigeon,Laetitia Nebot-Bral,Laetitia Nebot-Bral,Mélanie Desbois,Ester Simeone,Christine Mateus,L. Boselli,Jonathan Grivel,Emilie Soularue,Emilie Soularue,Patricia Lepage,Franck Carbonnel,Paolo A. Ascierto,Caroline Robert,Caroline Robert,Nathalie Chaput,Nathalie Chaput +32 more
TL;DR: It is shown that short-chain fatty acids, which are generated through bacterial fermentation, increases immune tolerance leading to resistance to anti-CTLA-4 immunotherapy in mice and patients with metastatic melanoma.
Journal ArticleDOI
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
Peng Liu,Liwei Zhao,Jonathan Pol,Sarah Levesque,Adriana Petrazzuolo,Christina Pfirschke,Camilla Engblom,Steffen Rickelt,Takahiro Yamazaki,Kristina Iribarren,Laura Senovilla,Lucillia Bezu,Erika Vacchelli,Valentina Sica,Andréa Melis,Tiffany Martin,Lin Xia,Heng Yang,Qingqing Li,Jinfeng Chen,Sylvère Durand,Fanny Aprahamian,Deborah Lefevre,Sophie Broutin,Angelo Paci,Angelo Paci,Amaury Bongers,Veronique Minard-Colin,Eric Tartour,Laurence Zitvogel,Lionel Apetoh,Yuting Ma,Mikael J. Pittet,Oliver Kepp,Guido Kroemer +34 more
TL;DR: It is shown that crizotinib is an effective stimulator of immunogenic cell death and can potentiate the efficacy of immune checkpoint blockade and can exert their anticancer effect through indirect immune-dependent mechanism.